C-type natriuretic peptide moderates titin-based cardiomyocyte stiffness.
Animals
Cyclic GMP
/ metabolism
Heart Failure
/ drug therapy
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Myocardium
/ metabolism
Myocytes, Cardiac
/ drug effects
Natriuretic Agents
/ pharmacology
Natriuretic Peptide, C-Type
/ pharmacology
Phosphorylation
Protein Kinases
/ genetics
Receptors, Atrial Natriuretic Factor
/ physiology
Cardiology
Cyclic nucleotides
Guanylate cyclase
Heart failure
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
19 11 2020
19 11 2020
Historique:
received:
04
05
2020
accepted:
09
10
2020
pubmed:
16
10
2020
medline:
8
6
2021
entrez:
15
10
2020
Statut:
epublish
Résumé
Heart failure is often accompanied by titin-dependent myocardial stiffness. Phosphorylation of titin by cGMP-dependent protein kinase I (PKGI) increases cardiomyocyte distensibility. The upstream pathways stimulating PKGI-mediated titin phosphorylation are unclear. We studied whether C-type natriuretic peptide (CNP), via its guanylyl cyclase-B (GC-B) receptor and cGMP/PKGI signaling, modulates titin-based ventricular compliance. To dissect GC-B-mediated effects of endogenous CNP in cardiomyocytes, we generated mice with cardiomyocyte-restricted GC-B deletion (CM GC-B-KO mice). The impact on heart morphology and function, myocyte passive tension, and titin isoform expression and phosphorylation was studied at baseline and after increased afterload induced by transverse aortic constriction (TAC). Pressure overload increased left ventricular endothelial CNP expression, with an early peak after 3 days. Concomitantly, titin phosphorylation at Ser4080, the site phosphorylated by PKGI, was augmented. Notably, in CM GC-B-KO mice this titin response was abolished. TAC-induced hypertrophy and fibrosis were not different between genotypes. However, the KO mice presented mild systolic and diastolic dysfunction together with myocyte stiffness, which were not observed in control littermates. In vitro, recombinant PKGI rescued reduced titin-Ser4080 phosphorylation and reverted passive stiffness of GC-B-deficient cardiomyocytes. CNP-induced activation of GC-B/cGMP/PKGI signaling in cardiomyocytes provides a protecting regulatory circuit preventing titin-based myocyte stiffening during early phases of pressure overload.
Identifiants
pubmed: 33055420
pii: 139910
doi: 10.1172/jci.insight.139910
pmc: PMC7710274
doi:
pii:
Substances chimiques
Natriuretic Agents
0
Natriuretic Peptide, C-Type
127869-51-6
Protein Kinases
EC 2.7.-
titin protein, mouse
EC 2.7.11.1
Receptors, Atrial Natriuretic Factor
EC 4.6.1.2
atrial natriuretic factor receptor B
EC 4.6.1.2
Cyclic GMP
H2D2X058MU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Biophys J. 1995 Mar;68(3):1027-44
pubmed: 7756523
Circ Res. 2013 Feb 15;112(4):664-74
pubmed: 23283722
Physiol Rev. 2016 Apr;96(2):751-804
pubmed: 27030537
Cardiovasc Res. 2013 Sep 1;99(4):648-56
pubmed: 23764881
Cardiovasc Res. 2018 Apr 1;114(5):656-667
pubmed: 29401264
Circulation. 2015 Apr 7;131(14):1247-59
pubmed: 25637629
Eur J Heart Fail. 2007 Jun-Jul;9(6-7):548-57
pubmed: 17407830
Am J Physiol Heart Circ Physiol. 2016 Jun 1;310(11):H1671-82
pubmed: 27059079
Circulation. 2013 Feb 26;127(8):938-44
pubmed: 23439446
Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17300-5
pubmed: 15572448
J Biol Chem. 2012 Aug 24;287(35):29273-84
pubmed: 22778266
Am J Physiol Heart Circ Physiol. 2018 Sep 1;315(3):H669-H680
pubmed: 29727215
Biophys J. 1994 Aug;67(2):782-92
pubmed: 7948691
J Mol Cell Cardiol. 2014 Oct;75:199-205
pubmed: 25117468
Endocrinology. 2003 Jun;144(6):2279-84
pubmed: 12746286
Cardiovasc Res. 2013 Mar 1;97(3):464-71
pubmed: 23213108
J Am Coll Cardiol. 2005 Feb 15;45(4):608-16
pubmed: 15708711
Int J Vasc Med. 2012;2012:246058
pubmed: 22848833
J Mol Cell Cardiol. 2016 Dec;101:145-155
pubmed: 27789290
Circulation. 2018 Jul 31;138(5):494-508
pubmed: 29626067
Eur Heart J. 2020 Mar 1;41(9):1006-1020
pubmed: 30903134
Int J Mol Sci. 2019 May 08;20(9):
pubmed: 31072047
Eur J Heart Fail. 2014 Sep;16(9):958-66
pubmed: 25082741
Biochem J. 1993 Apr 1;291 ( Pt 1):83-8
pubmed: 8097089
Endocrinology. 2004 May;145(5):2131-40
pubmed: 14749356
Circ Res. 2018 Jul 20;123(3):342-355
pubmed: 29760016
N Engl J Med. 2019 Oct 24;381(17):1609-1620
pubmed: 31475794
Eur Heart J. 2013 Apr;34(16):1233-44
pubmed: 22199120
Nat Commun. 2018 Jan 17;9(1):262
pubmed: 29343782
Circulation. 2003 Feb 4;107(4):571-3
pubmed: 12566368
Circ Res. 2009 Sep 25;105(7):631-8, 17 p following 638
pubmed: 19679839
FEBS J. 2019 Jun;286(12):2240-2260
pubmed: 30989819
Nat Commun. 2018 Jun 22;9(1):2446
pubmed: 29934640
Eur J Pharmacol. 2017 Oct 5;812:174-183
pubmed: 28697992
Circulation. 2012 Aug 14;126(7):830-9
pubmed: 22806632
Biochem Biophys Res Commun. 2007 Apr 27;356(1):60-6
pubmed: 17336931
Circ Res. 2009 Mar 27;104(6):780-6
pubmed: 19179657
Circulation. 2008 Apr 22;117(16):2051-60
pubmed: 18413502
N Engl J Med. 2014 Sep 11;371(11):993-1004
pubmed: 25176015
Nat Rev Cardiol. 2014 Jul;11(7):403-12
pubmed: 24820868
J Clin Invest. 2003 May;111(9):1399-407
pubmed: 12727932
J Surg Res. 2015 Apr;194(2):631-637
pubmed: 25483737
Circ Res. 2009 Jan 2;104(1):87-94
pubmed: 19023132